Mesna
Mesna is a protective medication given alongside the chemotherapy drug ifosfamide to prevent a serious bladder complication called hemorrhagic cystitis (bleeding in the bladder).
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 10 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Mesna: Patient Information Guide
A plain-language walkthrough of Mesna — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Mesna is a cytoprotective (cell-protecting) agent used alongside ifosfamide chemotherapy. All supported products share one core use:
- Preventing ifosfamide-induced hemorrhagic cystitis — serious bleeding and irritation of the bladder lining caused by toxic byproducts of ifosfamide. This applies to Mesna injection, Mesnex injection, Mesna tablets, and Mesnex tablets.
- Mesna injection, Mesnex injection, Mesna tablets, and Mesnex tablets are not indicated to reduce bladder bleeding due to other causes, such as thrombocytopenia (low platelet counts).
⚙️How it works▾
Ifosfamide breaks down in the body into toxic byproducts — particularly acrolein and 4-hydroxy-ifosfamide — that reach the bladder through urine and can cause severe irritation and bleeding. Mesna works by chemically bonding to these toxins in the urinary tract, converting them into harmless compounds before they can damage the bladder lining. It also binds directly to acrolein's reactive chemical bonds, further blocking its harmful effects. Mesna is essentially a targeted chemical neutralizer that works right where the damage would otherwise occur.
💊How it's taken▾
Mesna can be given in two ways — all by intravenous (IV) injection, or as an initial IV injection followed by oral tablets taken at set time intervals later. Both approaches are timed precisely around ifosfamide doses and repeated on every day that ifosfamide is given. If the ifosfamide dose is adjusted, the mesna dose is adjusted in proportion.
- IV-only schedule: Three IV bolus injections given at specific time points around each ifosfamide dose.
- IV-plus-oral schedule: One IV bolus injection at the time of ifosfamide, followed by two oral doses of mesna tablets at later time intervals. Food does not affect oral mesna's effectiveness in the bladder.
- If you vomit within two hours of an oral dose, tell your care team — you may need to repeat the dose or switch to IV.
- Always follow your prescriber's exact schedule; do not adjust the timing on your own.
🤒Side effects — in detail▾
Because mesna is given with ifosfamide chemotherapy, it can be hard to separate which side effects come from mesna versus the chemotherapy itself. The most commonly reported effects when mesna is used alongside ifosfamide include:
- Nausea and vomiting
- Fatigue or weakness
- Constipation or diarrhea
- Fever
- Loss of appetite
- Headache
- Drowsiness
- Injection site reactions (with IV use)
Serious reactions requiring immediate medical attention include severe allergic responses (anaphylaxis), dangerous skin reactions (including blistering or peeling), and seizures. If you experience any of these, seek help right away.
⚠️Warnings & precautions▾
- Severe allergic reactions (anaphylaxis): Mesna injection can trigger serious allergic reactions including low blood pressure, rapid heart rate, difficulty breathing, swelling, and organ effects. These can happen with the very first dose or after months of use. Stop the medication and get emergency care if this occurs.
- Dangerous skin reactions: Serious conditions such as Stevens-Johnson syndrome and toxic epidermal necrolysis (where skin blisters and peels away) have been reported. Any new rash, blistering, or mouth sores should prompt an immediate call to your doctor.
- Benzyl alcohol toxicity: Mesna injection contains benzyl alcohol as a preservative. This preservative has caused fatal reactions — including seizures, breathing problems, and organ failure — in premature newborns and low-birth-weight infants. The injectable form must never be used in those infants. Mesnex tablets do not contain benzyl alcohol.
- Lab test interference: Mesna can cause false-positive urine tests for ketones and false-low blood CPK (muscle enzyme) results. Always inform your lab team you are receiving mesna before any testing.
🔀What it interacts with▾
No formal clinical drug interaction studies have been conducted with mesna injection. However, there are important considerations to be aware of:
- Ifosfamide: Mesna is always given in direct combination with ifosfamide — the dose ratio between the two must be maintained whenever ifosfamide is adjusted.
- Other thiol compounds (e.g., amifostine): Patients who have had reactions to other sulfur-containing drugs may be at increased risk for reactions to mesna as well — tell your doctor about any prior reactions.
- Lab tests: Mesna can interfere with urine ketone tests and enzymatic CPK blood tests, potentially producing misleading results — always disclose mesna use before lab work.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Allergy to mesna or its ingredients: Do not use mesna if you have a known hypersensitivity to it or any of its components, including benzyl alcohol (present in the injectable form).
- Prior reactions to thiol compounds: Tell your doctor if you have ever reacted to amifostine or similar sulfur-containing drugs.
- Pregnancy: Ifosfamide, used alongside mesna, can harm a developing fetus. Tell your doctor immediately if you are pregnant or suspect you may be. Pregnancy status should be confirmed before starting treatment.
- Contraception: Women of childbearing potential should use effective contraception during treatment and for 6 months after the last dose. Men with female partners who could become pregnant should use contraception during treatment and for 3 months after the last dose.
- Breastfeeding: Do not breastfeed during treatment or for 1 week after the last dose of mesna or ifosfamide.
- Premature or low-birth-weight newborns: Mesna injection must not be used in this group due to serious and potentially fatal benzyl alcohol toxicity.
- Older adults: Dose selection should be handled carefully in elderly patients, given the higher likelihood of reduced kidney, liver, or heart function in this age group.
- Kidney or liver impairment: No clinical studies have evaluated how kidney or liver problems affect mesna's processing in the body — discuss your full medical history with your doctor.
🚑If you take too much▾
There is no known antidote if too much mesna is given. At very high doses, the most commonly reported effects include nausea, vomiting, diarrhea, and fever. Very large amounts have also been associated with allergic-type reactions such as low blood pressure, shortness of breath, rash, and flushing. If an overdose is suspected, contact your medical team or emergency services immediately.
📡Pharmacodynamics — effects in the body▾
Mesna works directly within the urinary tract, where it chemically neutralizes the bladder-toxic byproducts of ifosfamide — primarily acrolein and 4-hydroxy-ifosfamide. By binding to these compounds, it converts them into non-toxic forms before they can damage the bladder lining. Mesna does not interfere with ifosfamide's cancer-fighting effects in the rest of the body — its protective action is confined to the urinary system.
🔬Pharmacokinetics — how your body processes it▾
When taken by mouth, peak levels of mesna in the blood are reached within about 1.5 to 4 hours, and the drug is absorbed reasonably well orally. Food does not affect how much mesna reaches the urine. In the body, mesna is rapidly converted to an inactive form called dimesna (mesna disulfide); mesna itself clears from the blood very quickly, with a half-life of only about 22 minutes. Most of the drug is eliminated through the urine within 24 hours, which is precisely where it needs to be to protect the bladder.
📦How to store it▾
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F).
📄 Written from Mesna’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Mesna — the kind of thing our pharmacy team would talk through with you at the counter.
Why am I being given mesna? I thought I was here for chemotherapy. ▾
Do I take mesna as a pill or does it go through an IV? ▾
What side effects should I expect from mesna? ▾
Are there any skin reactions I should watch for? ▾
I'm pregnant — is it safe to take mesna? ▾
Will mesna affect any of my other lab tests? ▾
Is Mesna available over the counter? ▾
When was Mesna first available? ▾
Who makes Mesna? ▾
💬 Answers drafted from Mesna’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Mesna comes
Mesna is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Mesna injection and Mesnex injection are used to prevent ifosfamide-induced hemorrhagic cystitis (bladder bleeding caused by ifosfamide chemotherapy)
- Not indicated to reduce bleeding in the bladder from other causes such as low platelets
- Mesna injection and Mesnex injection are given as intravenous (IV) bolus injections timed to the ifosfamide schedule — at the time of ifosfamide administration and again at later intervals
- The dosing schedule is repeated on each day ifosfamide is given; if the ifosfamide dose changes, the mesna dose is adjusted to maintain the same ratio
- Mesnex injection contains benzyl alcohol — avoid use in premature newborns and low-birth-weight infants
- Maintain adequate fluid intake and urinary output as directed; urine should be monitored for blood during treatment
Tablet
How this form is used
- Mesna tablets and Mesnex tablets are used as part of a combined IV-then-oral schedule to prevent ifosfamide-induced hemorrhagic cystitis
- The combined IV-plus-oral regimen's established safety and effectiveness applies to ifosfamide daily doses up to 2 g/m² — higher doses have not been established for this schedule
- Mesna tablets and Mesnex tablets are taken orally at timed intervals after an initial IV dose of mesna — follow your care team's exact timing schedule
- Food does not affect how well oral mesna works in the bladder, so tablets can be taken with or without food
- If you vomit within two hours of taking oral mesna tablets, contact your care team — you may need to repeat the dose or receive IV mesna instead
- The tablet schedule is repeated on each day ifosfamide is given
📊 Mesna across the U.S. market
How Mesna appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (3) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Mesna is used
A general measure of how commonly Mesna is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Mesna is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Mesna prescribed? Of the 1,596 medications we measure, Mesna ranks #1,308 by Medicaid prescriptions — more than 18% of them.
Utilization by Mesna product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
mesna 100 MG/ML Injectable Solution Most dispensed
Summed across the 5 of 23 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 204870
mesna 400 MG Oral Tablet
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 142113
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Mesna, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 7 of 26 listed Mesna NDCs with Medicaid activity.
🔍 Compare Mesna products
A representative set of FDA-listed product records for Mesna — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 100 mg/mL | Intravenous | Bamboo US Bidco LCC | NDA | View NDC → |
| 100 mg/mL | Intravenous | Baxter Healthcare Company × 4 listings | NDA | View NDC → |
| 100 mg/mL | Intravenous | Baxter Healthcare Corporation × 8 listings | NDA | View NDC → |
| 100 mg/mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 100 mg/mL | Intravenous | Fresenius Kabi USA, LLC × 2 listings | ANDA | View NDC → |
| 100 mg/mL | Intravenous | Gland Pharma Limited | ANDA | View NDC → |
| 100 mg/mL | Intravenous | Hikma Farmaceutica | ANDA | View NDC → |
| 100 mg/mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 100 mg/mL | Intravenous | Sagent Pharmaceuticals × 2 listings | ANDA | View NDC → |
| 💊Tablet | ||||
| 400 mg | Oral | Baxter Healthcare Company × 2 listings | NDA | View NDC → |
| 400 mg | Oral | Baxter Healthcare Corporation × 2 listings | NDA | View NDC → |
| 400 mg | Oral | Ingenus Pharmaceuticals, LLC | ANDA | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Aarti Pharmalabs Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Solara Active Pharma Sciences Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Zhejiang Hisun Pharmaceutical Co., Ltd. | BULK INGREDIENT | View NDC → |
Showing 29 of 29 products — FDA National Drug Code Directory. See every product, package size and price: browse all 29 Mesna NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Mesna — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Mesna in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Mesna went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 44 2 dose forms · 3 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 374524In current FDA listingsClinical drug / strength (SCD) 100 MG/MLRxCUI 204870 -
Dose form (SCDF) Oral Tablet RxCUI 372790In current FDA listings
Look up RxCUI 44 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Mesna is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Mesna belongs to the Mucolytics class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 10 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Baxter Healthcare Corporation is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.